Biocept Akcija

Biocept EPS

Delisted

Peļņa uz akciju (EPS) no Biocept (BIOC) uz 2026. g. 22. aug. ir -1,88 USD. Iepriekšējā gadā Peļņa uz akciju (EPS) bija -0,17 USD — izmaiņas 1021,56 % (zemāks).

EPS

-1,88USD

YoY

1021,56%

Pēdējoreiz atjaunināts:

Peļņa uz akciju (EPS) no Biocept ir 2026 -1,88 USD. Peļņa uz akciju (EPS) no Biocept bija 2025 -0,17 USD. Tas samazinās par 1021,56% zemāks salīdzinājumā ar iepriekšējo gadu.

Biocept EPS vēsture

  • 3 gadi

  • 10 gadi

  • 25 gadi

  • Max

EPS
Date
EPS
2019. g. 1. janv.
-252,72 USD
2020. g. 1. janv.
-38,13 USD
2021. g. 1. janv.
-0,17 USD
2022. g. 1. janv.
-1,88 USD
2023. g. 1. janv. (e)
-166,50 USD
2024. g. 1. janv. (e)
-41,40 USD
2025. g. 1. janv. (e)
-25,50 USD
2026. g. 1. janv. (e)
-14,26 USD
Biocept EPS vēsture
GADSEPSYoY
est-14,26USD-44,06%
est-25,50USD-38,41%
est-41,40USD-75,14%
est-166,50USD+8757,70%
-1,88USD+1021,56%
-0,17USD-99,56%
-38,13USD-84,91%
-252,72USD-84,16%
-1595,56USD-73,42%
-6003,82USD-38,00%
-9683,85USD-60,01%
-24 213,61USD-69,48%
-79 330,23USD-94,27%
-1,38 MUSD-24,69%
-1,84 MUSD
Access this data via the Eulerpool API

Biocept Akciju analīze

Ko dara Biocept? Biocept Inc is a biotechnology company based in San Diego, California. It was founded in 1997 by Michael W. Nall, an experienced entrepreneur in the field of medical diagnostics and cancer research. Biocept specializes in the development of diagnostic tests and platforms aimed at the rapid and precise identification of cancer cells in the human body. The business model of Biocept focuses on the development of cancer diagnostic tests and selling them to medical labs, physician offices, and hospitals. The company offers a range of different diagnostic products that specialize in various types and stages of cancer. One of Biocept's most important products is a liquid biopsy test that allows medical professionals to quickly and effectively detect cancer cells in patients' blood. This test is particularly significant as it enables doctors to detect cancer at an early stage, thus improving treatment options and increasing the cure rate. Additionally, Biocept offers a variety of tests targeting specific types of cancer such as breast, lung, and prostate cancer. These tests are based on the analysis of tumor DNA extracted from tumor cells in biopsies or liquid biopsies. By accurately analyzing this DNA, medical professionals can determine the specific type and stage of the cancer, thus recommending the best treatment option. In order to expand its range of diagnostic products, Biocept has also entered into partnerships with other companies and research institutions in recent years. For example, in 2017, the company entered into a collaboration with Massachusetts General Hospital to develop a new panel of liquid biopsy tests specializing in the identification of cancer cells in various tissues and organs. Biocept has experienced strong growth in recent years, and its products are now sold in a variety of countries worldwide. The company works closely with medical professionals and research institutions to continuously improve its diagnostic products and develop new tests tailored to the needs of patients with cancer. The output isn't a question, so there is no answer needed. Biocept ir viens no populārākajiem uzņēmumiem Eulerpool.

Bieži uzdotie jautājumi par Biocept akciju

Biocept Peļņa uz akciju (EPS) 2026. gadā ir -1,88 USD.

Peļņa uz akciju (EPS) no Biocept mainījās no -0,17 USD uz -1,88 USD, kas atspoguļo 1021,56 % izmaiņas. Vērtība ir zemāks nekā iepriekšējā gadā.

Vietnē Eulerpool varat atrast pilnīgu Peļņa uz akciju (EPS) Biocept vēsturisko attīstību kopš 2006. gada — ar gada vērtībām, grafikiem un detalizētu analīzi.

Peļņa uz akciju mēra uzņēmuma peļņas daļu, sadalītu katrai apgrozībā esošajai akcijai.

EPS = Neto peļņa / Izdotās akcijas

Access this data via the Eulerpool API

Peļņas un zaudējumu aprēķins — Biocept

Visas kategorijas